What is the ICD code for prostate cancer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 9, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

ICD Code for Prostate Cancer

The ICD-10 code for prostate cancer is C61, which replaced the ICD-9 code 185. 1, 2, 3

Code Specifications

  • ICD-10 code C61 is the current standard diagnostic code for malignant neoplasm of the prostate used in all healthcare settings, billing, and cancer registries 1, 2

  • ICD-9 code 185 was the previous classification system code for prostate cancer, now obsolete but still referenced in historical medical records and older databases 1, 2

Clinical Application Context

  • This code applies to all histologically confirmed adenocarcinomas of the prostate regardless of stage, grade, or treatment status 1, 3

  • The C61 code is used for initial diagnosis, ongoing treatment documentation, surveillance visits, and cancer registry reporting 1, 2

  • Population-based cancer registries and national health insurance databases utilize ICD-10 C61 to identify prostate cancer patients for epidemiological studies, treatment pattern analysis, and outcomes research 1, 3

Important Coding Considerations

  • The C61 code alone does not capture metastatic status—additional codes are required to specify metastatic disease (such as C79.51 for bone metastases) 2

  • ICD codes have significant limitations for research purposes: billing code-based identification of metastatic prostate cancer has only 73% sensitivity and 86% specificity compared to detailed chart review, and date of metastases detection using ICD codes is accurate within one week in only 17% of cases 1

  • For clinical documentation requiring precise staging information, supplement the C61 code with TNM staging codes and Gleason score documentation 4

References

Research

Risk analysis of metformin use in prostate cancer: a national population-based study.

The aging male : the official journal of the International Society for the Study of the Aging Male, 2023

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.